Filomena Altieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Filomena Altieri has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Emilia Rippa
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
8 shared publications - Paolo Arcari
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy; CEINGE, Advanced Biotechnology Scarl, Via Gaetano Salvatore 486, I-80145, Naples, Italy
8 shared publications Chiara Stella Di Stadio
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
6 shared publications- Jessica Rosati
Cellular Reprogramming Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, Viale dei Cappuccini, 71013 San Giovanni Rotondo, FG, Italy; UniCamillus - Saint Camillus International University of Health Sciences, Via di Sant'Alessandro, 8- 00131 Rome, Italy
6 shared publications Giuseppe Lamorte
Fondazione IRCCS Casa Sollievo della Sofferenza, Molecular Genetics Unit, Viale dei Cappuccini, 71013, San Giovanni Rotondo, Foggia, Italy
5 shared publicationsGiuseppina Miselli
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
5 shared publications
Latest Publications
- Open Access
- 1 October 2019
- Published by Elsevier in Stem Cell Research
- Vol. 40, 101551
Generation of induced pluripotent stem cell line CSSi008-A (4698) from a patient affected by advanced stage of Dentato-Rubral-Pallidoluysian atrophy (DRPLA)
- 1 October 2019
- Published by Elsevier in Stem Cell Research
- Vol. 40, 101551
Open AccessGeneration of induced pluripotent stem cell line CSSi008-A (4698) from a patient affected by advanced stage of Dentato-Rubral-Pallidoluysian atrophy (DRPLA)
- Open Access
- 5 June 2019
- Published by Elsevier in Stem Cell Research
- Vol. 38, 101480
Production and characterization of human induced pluripotent stem cells (iPSC) CSSi007-A (4383) from Joubert Syndrome
- 5 June 2019
- Published by Elsevier in Stem Cell Research
- Vol. 38, 101480
Open AccessProduction and characterization of human induced pluripotent stem cells (iPSC) CSSi007-A (4383) from Joubert Syndrome
- Open Access
- 1 October 2018
- Published by Elsevier in Stem Cell Research
- Vol. 32, 73-77
Copy number variations in healthy subjects. Case study: iPSC line CSSi005-A (3544) production from an individual with variation in 15q13.3 chromosome duplicating gene CHRNA7
- 1 October 2018
- Published by Elsevier in Stem Cell Research
- Vol. 32, 73-77
Open AccessCopy number variations in healthy subjects. Case study: iPSC line CSSi005-A (3544) production from an individual with variation in 15q13.3 chromosome duplicating gene CHRNA7
- Open Access
- 17 September 2018
- Published by Springer Nature in Cell Death & Disease
- Vol. 9 (10) , 1-16
Establishment of stable iPS-derived human neural stem cell lines suitable for cell therapies
Establishing specific cell lineages from human induced pluripotent stem cells (hiPSCs) is vital for cell therapy approaches in regenerative medicine, particularly for neurodegenerative disorders. While neural precursors have been induced from hiPSCs, the establishment of hiPSC-derived human neural stem cells (hiNSCs), with characteristics that match foetal hNSCs and abide by cGMP standards, thus allowing clinical applications, has not been described. We generated hiNSCs by a virus-free technique, whose properties recapitulate those of the clinical-grade hNSCs successfully used in an Amyotrophic Lateral Sclerosis (ALS) phase I clinical trial. Ex vivo, hiNSCs critically depend on exogenous mitogens for stable self-renewal and amplification and spontaneously differentiate into astrocytes, oligodendrocytes and neurons upon their removal. In the brain of immunodeficient mice, hiNSCs engraft and differentiate into neurons and glia, without tumour formation. These findings now warrant the establishment of clinical-grade, autologous and continuous hiNSC lines for clinical trials in neurological diseases such as Huntington’s, Parkinson’s and Alzheimer’s, among others.
- 17 September 2018
- Published by Springer Nature in Cell Death & Disease
- Vol. 9 (10) , 1-16
Open AccessEstablishment of stable iPS-derived human neural stem cell lines suitable for cell therapies
Establishing specific cell lineages from human induced pluripotent stem cells (hiPSCs) is vital for cell therapy approaches in regenerative medicine, particularly for neurodegenerative disorders. While neural precursors have been induced from hiPSCs, the establishment of hiPSC-derived human neural stem cells (hiNSCs), with characteristics that match foetal hNSCs and abide by cGMP standards, thus allowing clinical applications, has not been described. We generated hiNSCs by a virus-free technique, whose properties recapitulate those of the clinical-grade hNSCs successfully used in an Amyotrophic Lateral Sclerosis (ALS) phase I clinical trial. Ex vivo, hiNSCs critically depend on exogenous mitogens for stable self-renewal and amplification and spontaneously differentiate into astrocytes, oligodendrocytes and neurons upon their removal. In the brain of immunodeficient mice, hiNSCs engraft and differentiate into neurons and glia, without tumour formation. These findings now warrant the establishment of clinical-grade, autologous and continuous hiNSC lines for clinical trials in neurological diseases such as Huntington’s, Parkinson’s and Alzheimer’s, among others.
- Open Access
- 1 April 2018
- Published by Elsevier in Stem Cell Research
- Vol. 28, 153-156
Production and characterization of CSSI003 (2961) human induced pluripotent stem cells (iPSCs) carrying a novel puntiform mutation in RAI1 gene, Causative of Smith–Magenis syndrome
- 1 April 2018
- Published by Elsevier in Stem Cell Research
- Vol. 28, 153-156
Open AccessProduction and characterization of CSSI003 (2961) human induced pluripotent stem cells (iPSCs) carrying a novel puntiform mutation in RAI1 gene, Causative of Smith–Magenis syndrome
- Open Access
- 1 March 2018
- Published by Elsevier in Stem Cell Research
- Vol. 27, 74-77
Production and characterization of human induced pluripotent stem cells (iPSCs) from Joubert Syndrome: CSSi001-A (2850)
- 1 March 2018
- Published by Elsevier in Stem Cell Research
- Vol. 27, 74-77
Open AccessProduction and characterization of human induced pluripotent stem cells (iPSCs) from Joubert Syndrome: CSSi001-A (2850)
- Open Access
- 25 January 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (10) , 16899-16911
Epigenetic alterations of gastrokine 1 gene expression in gastric cancer
Epigenetic alterations of gastrokine 1 gene expression in gastric cancer Epigenetic alterations of gastrokine 1 gene expression in gastric cancer
- 25 January 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (10) , 16899-16911
Open AccessEpigenetic alterations of gastrokine 1 gene expression in gastric cancer
Epigenetic alterations of gastrokine 1 gene expression in gastric cancer Epigenetic alterations of gastrokine 1 gene expression in gastric cancer
- Open Access
- 25 July 2016
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 15 (1) , 14
Gastrokine 1 mRNA in human sera is not informative biomarker for gastric cancer
We aimed to ascertain if Gastrokine 1 mRNA in the sera of patients with gastric cancer might be an informative biomarker for the disease. Analysis of GKN1 mRNA in serum samples from healthy individuals (n = 23) and from patients with diagnosis of gastric cancer (n = 16), performed by using absolute quantification based on standard curve method, did not show any significative statistical difference between the two unpaired group of individuals. Our preliminary results did not confirm GKN1 as a potential biomarker for gastric cancer.
- 25 July 2016
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 15 (1) , 14
Open AccessGastrokine 1 mRNA in human sera is not informative biomarker for gastric cancer
We aimed to ascertain if Gastrokine 1 mRNA in the sera of patients with gastric cancer might be an informative biomarker for the disease. Analysis of GKN1 mRNA in serum samples from healthy individuals (n = 23) and from patients with diagnosis of gastric cancer (n = 16), performed by using absolute quantification based on standard curve method, did not show any significative statistical difference between the two unpaired group of individuals. Our preliminary results did not confirm GKN1 as a potential biomarker for gastric cancer.